Drugs of Abuse Panel, Meconium - Screen with Reflex to Confirmation/Quantitation
Ordering Recommendation

Preferred meconium test to detect and document maternal drug use during pregnancy approximately the last trimester of a full-term birth. Targeted single-drug class testing is appropriate if only a particular drug class or classes are of clinical interest, or when quantity of meconium available for testing is very small (eg <1g).

Qualitative Enzyme-Linked Immunosorbent Assay/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
1-4 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
Patient Preparation
Meconium. All meconium (blackish material) excreted until milk/formula based stool (yellow-green) appears. 
Specimen Preparation
Transport all available meconium (4 g is preferred). (Min: 2 g or 3/4 inch cube on each side) 
Storage/Transport Temperature
Room temperature. 
Unacceptable Conditions
Ambient: 1 week; Refrigerated: 3 months; Frozen: 1 year 
Reference Interval
Drugs Covered and Cutoff Concentrations
Amphetamines30 ng/g20 ng/g
Barbiturates75 ng/g50 ng/g
Benzodiazepines75 ng/g20 ng/g
Buprenorphine40 ng/g20 ng/g
Cocaine30 ng/g20 ng/g
Marijuana30 ng/g5 ng/g
Methadone40 ng/g10 ng/g
Opiates30 ng/g20 ng/g
Phencyclidine15 ng/g10 ng/g

Interpretive Data
Meconium begins to form between the 12th and 16th week of gestation. Meconium drug testing can detect maternal drug use during the last 4 to 5 months of pregnancy. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drug use depends on the quantity and quality of the specimen tested as well as the pattern and frequency of drug(s) used by the mother. Although not likely, drugs administered during labor and delivery may be detected in meconium. Interpretive questions should be directed to the laboratory.

The concentration at which the screening test can detect a drug or metabolite varies within a drug class. The concentration value must be greater than or equal to the cutoff to be reported as positive.

For medical purposes only; not valid for forensic use.

Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

If the specimen screens positive, then Confirmation/Quantitation by LC-MS/MS will be added. Additional charges apply.

Unless ARUP is otherwise notified, reflex confirmation testing will be performed in the following order of priority:

Amphetamines (0.125 g sample required)
Cocaine (0.25 g sample required)
Opiates (0.125 g required)
Buprenorphine (0.125 g required)
Marijuana (0.125 g required)
Benzodiazepines (0.125 g sample required)
Methadone (0.125 g sample required)
Phencyclidine - PCP (0.25 g sample required)
Barbiturates (0.25 g sample required)
Hotline History
View Hotline History
CPT Code(s)
80307; if reflexed, add 80324; 80345; 80346; 80348; 80349; 80353; 80358; 80359; 80361; 80365; 83992 (Reflexed Alt Code: G0480 )
Component Test Code*Component Chart NameLOINC
0092020Marijuana, Meconium31136-5
0092021Cocaine, Meconium26956-3
0092022Opiates, Meconium29158-3
0092023Phencyclidine, Meconium26859-9
0092024Amphetamines, Meconium26895-3
0092318Methadone, Meconium29159-1
0092319Barbiturates, Meconium29161-7
0092517Meconium Comments58738-6
0092518Benzodiazepines, Meconium29160-9
2011913Buprenorphine, Meconium77205-3
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
  • Pain Management